BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

605 related articles for article (PubMed ID: 29977059)

  • 21. EWS-FLI1-mediated suppression of the RAS-antagonist Sprouty 1 (SPRY1) confers aggressiveness to Ewing sarcoma.
    Cidre-Aranaz F; Grünewald TG; Surdez D; García-García L; Carlos Lázaro J; Kirchner T; González-González L; Sastre A; García-Miguel P; López-Pérez SE; Monzón S; Delattre O; Alonso J
    Oncogene; 2017 Feb; 36(6):766-776. PubMed ID: 27375017
    [TBL] [Abstract][Full Text] [Related]  

  • 22. USP19 deubiquitinates EWS-FLI1 to regulate Ewing sarcoma growth.
    Gierisch ME; Pedot G; Walser F; Lopez-Garcia LA; Jaaks P; Niggli FK; Schäfer BW
    Sci Rep; 2019 Jan; 9(1):951. PubMed ID: 30700749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systematic multi-omics cell line profiling uncovers principles of Ewing sarcoma fusion oncogene-mediated gene regulation.
    Orth MF; Surdez D; Faehling T; Ehlers AC; Marchetto A; Grossetête S; Volckmann R; Zwijnenburg DA; Gerke JS; Zaidi S; Alonso J; Sastre A; Baulande S; Sill M; Cidre-Aranaz F; Ohmura S; Kirchner T; Hauck SM; Reischl E; Gymrek M; Pfister SM; Strauch K; Koster J; Delattre O; Grünewald TGP
    Cell Rep; 2022 Dec; 41(10):111761. PubMed ID: 36476851
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional Genomic Screening Reveals Splicing of the EWS-FLI1 Fusion Transcript as a Vulnerability in Ewing Sarcoma.
    Grohar PJ; Kim S; Rangel Rivera GO; Sen N; Haddock S; Harlow ML; Maloney NK; Zhu J; O'Neill M; Jones TL; Huppi K; Grandin M; Gehlhaus K; Klumpp-Thomas CA; Buehler E; Helman LJ; Martin SE; Caplen NJ
    Cell Rep; 2016 Jan; 14(3):598-610. PubMed ID: 26776507
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy.
    Kovar H
    Expert Opin Ther Targets; 2014 Nov; 18(11):1315-28. PubMed ID: 25162919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting the CALCB/RAMP1 axis inhibits growth of Ewing sarcoma.
    Dallmayer M; Li J; Ohmura S; Alba Rubio R; Baldauf MC; Hölting TLB; Musa J; Knott MML; Stein S; Cidre-Aranaz F; Wehweck FS; Romero-Pérez L; Gerke JS; Orth MF; Marchetto A; Kirchner T; Bach H; Sannino G; Grünewald TGP
    Cell Death Dis; 2019 Feb; 10(2):116. PubMed ID: 30741933
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of two types of GGAA-microsatellites and their roles in EWS/FLI binding and gene regulation in Ewing sarcoma.
    Johnson KM; Taslim C; Saund RS; Lessnick SL
    PLoS One; 2017; 12(11):e0186275. PubMed ID: 29091716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The orphan nuclear receptor DAX1 is up-regulated by the EWS/FLI1 oncoprotein and is highly expressed in Ewing tumors.
    Mendiola M; Carrillo J; García E; Lalli E; Hernández T; de Alava E; Tirode F; Delattre O; García-Miguel P; López-Barea F; Pestaña A; Alonso J
    Int J Cancer; 2006 Mar; 118(6):1381-9. PubMed ID: 16206264
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Primary subcutaneous spindle cell Ewing sarcoma with strong S100 expression and EWSR1-FLI1 fusion: a case report.
    Arnold MA; Ballester LY; Pack SD; Abdullaev Z; Merchant M; Tsokos MG
    Pediatr Dev Pathol; 2014; 17(4):302-7. PubMed ID: 24735198
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ewing sarcoma with FEV gene rearrangements is a rare subset with predilection for extraskeletal locations and aggressive behavior.
    Tsuda Y; Dickson BC; Swanson D; Sung YS; Zhang L; Meyers P; Healey JH; Antonescu CR
    Genes Chromosomes Cancer; 2020 May; 59(5):286-294. PubMed ID: 31756779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The prognostic signature of the somatic mutations in Ewing sarcoma: from a network view.
    Zhang Y; Song J; Shi Q; Song X; Shen L; Zhou J; Shao J
    Jpn J Clin Oncol; 2019 Jul; 49(7):604-613. PubMed ID: 30927420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long noncoding RNA EWSAT1-mediated gene repression facilitates Ewing sarcoma oncogenesis.
    Marques Howarth M; Simpson D; Ngok SP; Nieves B; Chen R; Siprashvili Z; Vaka D; Breese MR; Crompton BD; Alexe G; Hawkins DS; Jacobson D; Brunner AL; West R; Mora J; Stegmaier K; Khavari P; Sweet-Cordero EA
    J Clin Invest; 2014 Dec; 124(12):5275-90. PubMed ID: 25401475
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The second European interdisciplinary Ewing sarcoma research summit--A joint effort to deconstructing the multiple layers of a complex disease.
    Kovar H; Amatruda J; Brunet E; Burdach S; Cidre-Aranaz F; de Alava E; Dirksen U; van der Ent W; Grohar P; Grünewald TG; Helman L; Houghton P; Iljin K; Korsching E; Ladanyi M; Lawlor E; Lessnick S; Ludwig J; Meltzer P; Metzler M; Mora J; Moriggl R; Nakamura T; Papamarkou T; Radic Sarikas B; Rédini F; Richter GH; Rossig C; Schadler K; Schäfer BW; Scotlandi K; Sheffield NC; Shelat A; Snaar-Jagalska E; Sorensen P; Stegmaier K; Stewart E; Sweet-Cordero A; Szuhai K; Tirado OM; Tirode F; Toretsky J; Tsafou K; Üren A; Zinovyev A; Delattre O
    Oncotarget; 2016 Feb; 7(8):8613-24. PubMed ID: 26802024
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein.
    Hahm KB; Cho K; Lee C; Im YH; Chang J; Choi SG; Sorensen PH; Thiele CJ; Kim SJ
    Nat Genet; 1999 Oct; 23(2):222-7. PubMed ID: 10508522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cell-to-cell heterogeneity of EWSR1-FLI1 activity determines proliferation/migration choices in Ewing sarcoma cells.
    Franzetti GA; Laud-Duval K; van der Ent W; Brisac A; Irondelle M; Aubert S; Dirksen U; Bouvier C; de Pinieux G; Snaar-Jagalska E; Chavrier P; Delattre O
    Oncogene; 2017 Jun; 36(25):3505-3514. PubMed ID: 28135250
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus.
    Harlow ML; Maloney N; Roland J; Guillen Navarro MJ; Easton MK; Kitchen-Goosen SM; Boguslawski EA; Madaj ZB; Johnson BK; Bowman MJ; D'Incalci M; Winn ME; Turner L; Hostetter G; Galmarini CM; Aviles PM; Grohar PJ
    Cancer Res; 2016 Nov; 76(22):6657-6668. PubMed ID: 27697767
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EWS-FLI1 perturbs MRTFB/YAP-1/TEAD target gene regulation inhibiting cytoskeletal autoregulatory feedback in Ewing sarcoma.
    Katschnig AM; Kauer MO; Schwentner R; Tomazou EM; Mutz CN; Linder M; Sibilia M; Alonso J; Aryee DNT; Kovar H
    Oncogene; 2017 Oct; 36(43):5995-6005. PubMed ID: 28671673
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hippo pathway effectors YAP1/TAZ induce an EWS-FLI1-opposing gene signature and associate with disease progression in Ewing sarcoma.
    Rodríguez-Núñez P; Romero-Pérez L; Amaral AT; Puerto-Camacho P; Jordán C; Marcilla D; Grünewald TG; Alonso J; de Alava E; Díaz-Martín J
    J Pathol; 2020 Apr; 250(4):374-386. PubMed ID: 31880317
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss of Stag2 cooperates with EWS-FLI1 to transform murine Mesenchymal stem cells.
    El Beaino M; Liu J; Wasylishen AR; Pourebrahim R; Migut A; Bessellieu BJ; Huang K; Lin PP
    BMC Cancer; 2020 Jan; 20(1):3. PubMed ID: 31898537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
    Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
    Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.